FDA is “redoubling” harmonization efforts
This article was originally published in The Gold Sheet
Executive Summary
FDA is working on an exchange of letters with Japan; developing a Memorandum of Understanding with Switzerland; working on a MOU with Australia; and developing an exchange of letters as well as a mutual recognition agreement with the EU, reported Friedman at the June 23 Pharma Conference. In addition, FDA is working on a MOU with Canada, and developing a trilateral cooperation agreement with Canada and Mexico. As a result of these agreements with the EU in particular, Friedman reported that "we could potentially be doing less inspections in the EU in the next couple of years … and more inspections in the emerging economies of China and India." He added that "we are interested in harmonization. We are seeking membership in PIC/S for the reason that PIC/S has more members and more harmonized techniques than ICH
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.